Allergan, Inc. (AGN) Tops Q3 EPS by 2c; Guides Q4 Below, FY11 In-Line

Allergan, Inc. (NYSE: AGN) reported Q3 EPS of $0.92, $0.02 better than the analyst estimate of $0.90. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.33 billion.

Allergan, Inc. sees FY2011 EPS of $3.62-$3.64, versus the consensus of $3.64. Allergan, Inc. sees FY2011 revenue of $5.295-$5.390 billion, versus the consensus of $5.42 billion.

Allergan, Inc. sees Q4 2011 EPS of $0.97-$0.99, versus the consensus of $1.01. Allergan, Inc. sees Q4 2011 revenue of $1.330-$1.405 billion, versus the consensus of $1.41 billion.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UnitedHealth Group (UNH) Tops Q3 EPS by 57c, Beats on Revenue; Offers FY EPS Guidance
• Neogen Corp. (NEOG) Tops Q1 EPS by 3c
• Cryo-Cell International, Inc. (CCEL) Tops Q3 EPS by 13c